Payal Jain

Employment

• Day One Biopharmaceuticals Principal Scientist
  2021 - Present
• The Children's Hospital of Philadelphia Senior Scientist
  2020 - 2021
• The Children's Hospital of Philadelphia Scientist I
  2016 - 2020
• Columbia University Medical Center Research Assitant
  2011 - 2012

Education

• University of Pennsylvania Perelman School of Medicine PhD
  2012 - 2016
• Columbia University Master of Arts
  2010 - 2011
• Amity University B. Tech (Biotechnology)
  2006 - 2010

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Genomic Analysis of Dysembryoplastic Neuroepithelial Tumor Spectrum Reveals a Diversity of Molecular Alterations Dysregulating the MAPK and PI3K/mTOR Pathways
  Journal of Neuropathology & Experimental Neurology 2019 63 citations DOI: 10.1093/jnen/nlz101
  +Save
• Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway
  Pediatric and Developmental Pathology 2019 13 citations DOI: 10.1177/1093526619864230
  +Save
• A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: A report from the Pacific Pediatric Neuro‐Oncology Consortium
  International Journal of Cancer 2019 135 citations DOI: 10.1002/ijc.32258
  +Save
• Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation
  Acta neuropathologica 2018 29 citations DOI: 10.1007/s00401-018-1864-5
  +Save
• Purification of mRNA encoding chimeric antigen receptor is critical for generation of robust T cell response
  Human gene therapy 2018 137 citations DOI: 10.1089/hum.2018.145
  +Save
• Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases
  Bone 2018 34 citations DOI: 10.1016/j.bone.2017.08.001
  +Save
• CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles
  Oncogene 2017 75 citations DOI: 10.1038/onc.2017.276
  +Save
• LGG-09. PEDIATRIC LOW-GRADE GLIOMAS WITH CRAF GENE FUSIONS ARE THERAPEUTICALLY DISTINCT FROM BRAF-FUSIONS BASED ON DIMERIZATION MEDIATED BY N-TERMINAL FUSION PARTNER
  Neuro-oncology 2017 0 citations DOI: 10.1093/neuonc/nox083.142
  +Save
• MYB-QKI drives childhood brain tumors via tripartite mechanism
  Cell cycle (Georgetown, Tex.) 2017 5 citations DOI: 10.1080/15384101.2016.1260990
  +Save
• Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
  Oncotarget 2017 45 citations DOI: 10.18632/oncotarget.20949
  +Save